Satellite Symposium


  • September 1 (THU)
  • September 2 (FRI)

Satellite Symposium 1
ASCO

New era of NSCLC EGFR mutation treatment_Updated overall survival analysis: 3G EGFR TKI Lazertinib
Date & Time Sep. 1 (Thu), 9:00-9:40 Venue Room D
Chair
  • Myung-Ju Ahn (Samsung Medical Center, Korea)
Presentation
Detail
  1. Lazertinib, a new game-changer in EGFR-mutant NSCLC
    Ji-Youn Han (National Cancer Center, Korea)

Satellite Symposium 2
ASCO

Efficacy and safety of Gavreto for RET+ patients
Date & Time Sep. 1 (Thu), 9:50-10:30 Venue Room D
Chair
  • Byoung Yong Shim (The Catholic University of Korea St. Vincent’s Hospital, Korea)
Presentation
Detail
  1. The welcome rain, Gavreto: New hope for RET+ patients
    Dae Ho Lee (Asan Medical Center, Korea)

Satellite Symposium 3
ASCO

What is the roles of Lonsurf (FTD/TPI) for the treatment of CRC/GC patients?
Date & Time Sep. 1 (Thu), 12:40-13:20 Venue Room C
Chair
  • Hei-Cheul Jeung (Gangnam Severance Hospital, Korea)
Presentation
Detail
  1. 1.The role of FTD/TPI in treatment of patients with mCRC
    Ji Hyung Hong (The Catholic University of Korea Eunpyeong St. Mary's Hospital, Korea)
  2. 2.The role of FTD/TPI in treatment of patients with mGC
    Hyung-Don Kim (Asan Medical Center, Korea)

Satellite Symposium 4
ASCO

Delving deeper into the 1st & 2nd line setting CDK4/6 inhibitor data (abemaciclib) for patients with HR+ HER2- metastatic breast cancer
Date & Time Sep. 1 (Thu), 12:40-13:20 Venue Room D
Chairs
  • Sung-Bae Kim (Asan Medical Center, Korea)
Presentation
Detail
  1. Delving deeper into the 1st & 2nd line setting CDK4/6 inhibitor data (abemaciclib) for patients with HR+ HER2- metastatic breast cancer
    Antonio Llombart (Hospital Arnau Vilanova, Spain)

Satellite Symposium 5
ASCO

Treatment strategy for uHCC patients: What can we expect from TKIs in uHCC treatment?
Date & Time Sep. 1 (Thu), 13:30-14:10 Venue Room C
Chair
  • Baek-Yeol Ryoo (Asan Medical Center, Korea)
Presentation
Detail
  1. 1.The current role of Lenvatinib in Japanese clinical practice
    Masayuki Kurosaki (Musashino Red Cross Hospital, Japan)
  2. 2.What can we expect from TKIs in uHCC treatment?
    Jaekyung Cheon (Cha Bundang Medical Center, Korea)

Satellite Symposium 6
ASCO

Palbociclib as first in class CDK4/6 inhibitor: Milestones since 2015 FDA approval
Date & Time Sep. 1 (Thu), 13:30-14:10 Venue Room D
Chairs
  • Eun Kyung Cho (Gachon University Gil Medical Center, Korea)
Presentation
Detail
  1. Overall survival with Palbociclib: First in class CDK4/6 inhibitor in HR+ HER2- mBC
    Hee Kyung Ahn (Gachon University Gil Medical Center, Korea)

Satellite Symposium 7
ASCO

Integrating novel agents into the treatment paradigm for advanced urothelial carcinoma
Date & Time Sep. 1 (Thu), 15:50-16:30 Venue Room D
Chair
  • Sang Joon Shin (Yonsei Cancer Center, Korea)
Presentation
Detail
  1. Integrating novel agents into the treatment paradigm for la/mUC: current and future perspective
    Yoon Ji Choi (Korea University Anam Hospital, Korea)

Satellite Symposium 8
ASCO

Perspective change for first line treatment strategy in advanced renal cell carcinoma
Date & Time Sep. 1 (Thu), 16:40-17:20 Venue Room D
Chair
  • Se Hoon Park (Samsung Medical Center, Korea)
Presentation
Detail
  1. Clinical Benefits of 1L aRCC patient with two-year follow-up in CheckMate9ER
    Inkeun Park (Asan Medical Center, Korea)